The new relationship will add significant scale and reach to Rhinomed's footprint by bringing to bear BOC's considerable presence in sleep services and sleep apnea products. In addition, Mute will also be sold into mainstream retail through convenience stores nationwide.
As Rhinomed CEO Michael Johnson says: "We have a compelling solution for the 1 in 4 people who suffer from nasal congestion and the almost 1 in 2 who snore. This regional relationship with BOC and Linde, as one of the biggest suppliers of CPAP and sleep services, is a watermark milestone for Rhinomed. It ensures that Mute can be a frontline solution for the millions of Australians who want to investigate how they can stop snoring and start sleeping better."
Rhinomed has enjoyed a rapid trajectory over the past 12 months, launching into the UK and US and securing its presence in top tier pharmacies such as Boots, Walgreens, CVS Health as well as opening up wholesaling agreements with McKessons. Mute is also sold through Linde Group's US operation Lincare, which sells its Mute technology through the 1800cpap.com site.
Rhinomed's technology provides a frontline solution to sleep disordered breathing which can result in a variety of sleep problems. Mute complements BOC's current sleep offering by providing an affordable, easy-to-use product for assisting with nasal congestion and snoring.
Mike Danielson, Media Relations Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rhinomed-and-the-linde-group-team-up-to-transform-australian-sleep-market-300374345.html
SOURCE Rhinomed Limited